Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1936 1
1937 1
1939 2
1946 3
1947 2
1948 5
1949 2
1951 2
1952 1
1953 1
1954 1
1956 3
1959 2
1960 1
1963 1
1965 1
1966 2
1967 5
1968 3
1969 3
1970 2
1971 4
1972 2
1973 2
1974 5
1975 4
1976 5
1977 2
1978 8
1979 6
1980 9
1981 3
1982 7
1983 6
1984 3
1985 7
1986 9
1987 4
1988 7
1989 15
1990 15
1991 16
1992 10
1993 22
1994 17
1995 19
1996 17
1997 18
1998 16
1999 16
2000 19
2001 12
2002 15
2003 15
2004 15
2005 12
2006 11
2007 21
2008 31
2009 20
2010 36
2011 33
2012 26
2013 23
2014 31
2015 26
2016 16
2017 28
2018 32
2019 41
2020 42
2021 40
2022 29
2023 4
Text availability
Article attribute
Article type
Publication date

Search Results

831 results
Results by year
Filters applied: . Clear all
Page 1
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ. Perl AE, et al. Among authors: stuart r. N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688. N Engl J Med. 2019. PMID: 31665578 Clinical Trial.
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM. DiNardo CD, et al. Among authors: stuart rk. N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2. N Engl J Med. 2018. PMID: 29860938 Free article. Clinical Trial.
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC. Lancet JE, et al. Among authors: stuart rk. J Clin Oncol. 2018 Sep 10;36(26):2684-2692. doi: 10.1200/JCO.2017.77.6112. Epub 2018 Jul 19. J Clin Oncol. 2018. PMID: 30024784 Free PMC article. Clinical Trial.
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.
Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, Pigneux A, Wetzler M, Stuart RK, Erba HP, Damon LE, Powell BL, Lindeman N, Steensma DP, Wadleigh M, DeAngelo DJ, Neuberg D, Stone RM, Ebert BL. Lindsley RC, et al. Among authors: stuart rk. Blood. 2015 Feb 26;125(9):1367-76. doi: 10.1182/blood-2014-11-610543. Epub 2014 Dec 30. Blood. 2015. PMID: 25550361 Free PMC article.
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial.
Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Faderl S, Cortes JE. Lancet JE, et al. Among authors: stuart rk. Lancet Haematol. 2021 Jul;8(7):e481-e491. doi: 10.1016/S2352-3026(21)00134-4. Lancet Haematol. 2021. PMID: 34171279 Clinical Trial.
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M. Perl AE, et al. Among authors: stuart r. Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20. Lancet Oncol. 2017. PMID: 28645776 Free PMC article. Clinical Trial.
Salivary gland neoplasms.
Day TA, Deveikis J, Gillespie MB, Joe JK, Ogretmen B, Osguthorpe JD, Reed SG, Richardson MS, Rossi M, Saini R, Sharma AK, Stuart RK. Day TA, et al. Among authors: stuart rk. Curr Treat Options Oncol. 2004 Feb;5(1):11-26. doi: 10.1007/s11864-004-0002-x. Curr Treat Options Oncol. 2004. PMID: 14697153 Review.
Moving Ahead with a New
Campion EW, Scott LA, Muenning JE, Stern KL, Gartside MA, Frazier KM, Burns NS, Lawlor AJ, Prince JM, Stuart RJ, Morrissey S, Drazen JM. Campion EW, et al. Among authors: stuart rj. N Engl J Med. 2018 Feb 8;378(6):574. doi: 10.1056/NEJMe1800731. Epub 2018 Jan 22. N Engl J Med. 2018. PMID: 29365281 Free article. No abstract available.
O-Mannosylation and human disease.
Dobson CM, Hempel SJ, Stalnaker SH, Stuart R, Wells L. Dobson CM, et al. Among authors: stuart r. Cell Mol Life Sci. 2013 Aug;70(16):2849-57. doi: 10.1007/s00018-012-1193-0. Epub 2012 Nov 1. Cell Mol Life Sci. 2013. PMID: 23115008 Free PMC article. Review.
Oral cancer treatment.
Day TA, Davis BK, Gillespie MB, Joe JK, Kibbey M, Martin-Harris B, Neville B, Reed SG, Richardson MS, Rosenzweig S, Sharma AK, Smith MM, Stewart S, Stuart RK. Day TA, et al. Among authors: stuart rk. Curr Treat Options Oncol. 2003 Feb;4(1):27-41. doi: 10.1007/s11864-003-0029-4. Curr Treat Options Oncol. 2003. PMID: 12525277 Review.
831 results